Announcement on the Voluntary Disclosure Regarding the Initiation of Phase III Clinical Trial for GR1802 Injection in the Indication of Chronic Spontaneous Urticaria

About this update from Chongqing Genrix Biopharmaceutical Co., Ltd. Class A

Announcement on the Voluntary Disclosure Regarding the Initiation of Phase III Clinical Trial for GR1802 Injection in the Indication of Chronic Spontaneous UrticariaThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Chongqing Genrix Biopharmaceutical Co., Ltd. Class A